Roubaix Capital LLC acquired a new stake in shares of STAAR Surgical Company (NASDAQ:STAA – Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 151,315 shares of the medical instruments supplier’s stock, valued at approximately $3,421,000.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. State of Wyoming acquired a new position in STAAR Surgical during the 3rd quarter valued at about $66,000. Angeles Wealth Management LLC acquired a new stake in STAAR Surgical in the second quarter worth about $209,000. Arizona State Retirement System acquired a new stake in STAAR Surgical in the second quarter worth about $235,000. Fifth Third Bancorp boosted its holdings in STAAR Surgical by 2,867.1% in the first quarter. Fifth Third Bancorp now owns 11,008 shares of the medical instruments supplier’s stock worth $206,000 after acquiring an additional 10,637 shares in the last quarter. Finally, Amundi purchased a new stake in shares of STAAR Surgical during the first quarter worth about $305,000. 96.70% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several equities analysts have recently issued reports on STAA shares. Wedbush cut their price objective on shares of STAAR Surgical from $40.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Piper Sandler reissued a “neutral” rating on shares of STAAR Surgical in a research report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of STAAR Surgical in a report on Wednesday, November 11th. Veritas Investment Research set a $31.00 price target on shares of STAAR Surgical in a report on Tuesday, September 29th. Finally, Stifel Nicolaus raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and boosted their price objective for the company from $28.00 to $31.00 in a report on Tuesday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $29.00.
STAAR Surgical Trading Down 1.7%
Shares of STAA opened at $25.56 on Wednesday. The firm has a market cap of $1.28 billion, a P/E ratio of -2,556,000.00 and a beta of 1.22. The stock’s 50 day moving average is $23.05 and its two-hundred day moving average is $23.88. STAAR Surgical Company has a 12 month low of $15.59 and a 12 month high of $35.87.
STAAR Surgical (NASDAQ:STAA – Get Free Report) last released its earnings results on Wednesday, November 4th. The medical instruments supplier reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.06. STAAR Surgical had a return on equity of 8.43% and a net margin of 0.16%. The business had revenue of $83.41 million for the quarter, compared to the consensus estimate of $78.73 million. During the same quarter last year, the business posted $0.08 earnings per share. The business’s quarterly revenue was down 11.9% compared to the same quarter last year. Equities research analysts forecast that STAAR Surgical Company will post 0.43 EPS for the current year.
STAAR Surgical announced that its board has authorized a stock repurchase plan on Thursday, September 24th that permits the company to repurchase $50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to reacquire up to 5.2% of its stock through open market purchases. Share repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
About STAAR Surgical
STAAR Surgical is a medical device company focused on ophthalmic surgery and vision correction. The company develops, manufactures and markets implantable lenses and related products designed to reduce or eliminate dependence on glasses or contact lenses. Its principal product line is the EVO Visian Implantable Collamer Lens (ICL), a lens implanted inside the eye to correct myopia, with or without astigmatism. Unlike procedures that remove corneal tissue, ICL surgery preserves the eye’s natural lens and is designed to be removable.
Featured Stories
- Five stocks we like better than STAAR Surgical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical Company (NASDAQ:STAA – Free Report).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.
